Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

45.71 +0.94 (+2.10%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Spruce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 08, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 03, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Joins the Russell 3000® Index

June 29, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

June 22, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

June 15, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

June 08, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

May 28, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in Upcoming Conferences in June

May 27, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

May 04, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

April 20, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

April 20, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

March 09, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

March 09, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Present at Upcoming Investor Conferences in March

March 02, 2026

From Spruce Biosciences, Inc.

Via Business Wire

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy ↗

February 18, 2026

Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.

Via Stocktwits

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

February 18, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

February 05, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

February 03, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

January 28, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

January 08, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

December 15, 2025

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Inc (NASDAQ:SPRB) Reports Q3 2025 Results, Secures $50M Financing and Breakthrough Therapy Designation ↗

November 10, 2025

Spruce Biosciences reports Q3 2025 results, secures $50M financing and Breakthrough Therapy Designation for its lead drug candidate.

Via Chartmill

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 10, 2025

From Spruce Biosciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.